Swiss National Bank
PBYI icon

Swiss National Bank’s Puma Biotechnology PBYI Stock Holding History

Swiss National Bank’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-66,530
Closed -$466K – 2746
2021
Q3 		$466K Hold
66,530
– – ﹤0.01% 2590
2021
Q2 		$611K Sell
66,530
-9,300
-12% -$94.2K ﹤0.01% 2600
2021
Q1 		$737K Hold
75,830
– – ﹤0.01% 2414
2020
Q4 		$778K Hold
75,830
– – ﹤0.01% 2385
2020
Q3 		$765K Buy
75,830
+1,900
+3% +$19.3K ﹤0.01% 2230
2020
Q2 		$771K Buy
73,930
+14,400
+24% +$149K ﹤0.01% 2243
2020
Q1 		$502K Hold
59,530
– – ﹤0.01% 2173
2019
Q4 		$521K Buy
59,530
+2,800
+5% +$23.2K ﹤0.01% 2409
2019
Q3 		$611K Hold
56,730
– – ﹤0.01% 2285
2019
Q2 		$722K Buy
56,730
+1,100
+2% +$25.3K ﹤0.01% 2292
2019
Q1 		$2.15M Buy
55,630
+1,800
+3% +$55K ﹤0.01% 1617
2018
Q4 		$1.09M Buy
53,830
+1,900
+4% +$57K ﹤0.01% 1955
2018
Q3 		$2.38M Hold
51,930
– – ﹤0.01% 1609
2018
Q2 		$3.07M Hold
51,930
– – ﹤0.01% 1423
2018
Q1 		$3.53M Buy
51,930
+1,200
+2% +$89.9K ﹤0.01% 1272
2017
Q4 		$5.01M Buy
50,730
+1,700
+3% +$190K 0.01% 1061
2017
Q3 		$5.87M Hold
49,030
– – 0.01% 929
2017
Q2 		$4.29M Sell
49,030
-5,700
-10% -$319K 0.01% 1091
2017
Q1 		$2.04M Buy
54,730
+1,100
+2% +$40.1K ﹤0.01% 1550
2016
Q4 		$1.65M Buy
53,630
+10,000
+23% +$432K ﹤0.01% 1700
2016
Q3 		$2.92M Sell
43,630
-1,500
-3% -$75.8K ﹤0.01% 1261
2016
Q2 		$1.34M Hold
45,130
– – ﹤0.01% 1782
2016
Q1 		$1.28M Buy
45,130
+9,100
+25% +$411K ﹤0.01% 1754
2015
Q4 		$2.83M Sell
36,030
-15,570
-30% -$1.22M 0.01% 1101
2015
Q3 		$3.89M Buy
51,600
+5,200
+11% +$492K 0.01% 908
2015
Q2 		$5.42M Buy
46,400
+16,000
+53% +$2.9M 0.01% 732
2015
Q1 		$7.18M Buy
30,400
+400
+1% +$85.5K 0.02% 638
2014
Q4 		$5.68M Buy
30,000
+2,600
+9% +$577K 0.02% 645
2014
Q3 		$6.54M Sell
27,400
-500
-2% -$103K 0.03% 572
2014
Q2 		$1.84M Buy
+27,900
New +$1.98M 0.01% 1307

Other funds holding PBYI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Swiss National Bank's PBYI Position: Q4 2021 in Review

Swiss National Bank sold out of Puma Biotechnology (PBYI) in Q4 2021, closing a stake of 66,530 shares — an estimated $466K sold.

Swiss National Bank first reported a position in PBYI in Q2 2014 and held it in 30 quarters. The position peaked at $7.18M in Q1 2015. 102 funds tracked by Wall St. Rank hold PBYI as of Q4 2021.

  • Swiss National Bank reported no remaining Puma Biotechnology position as of Q4 2021 after selling out during the quarter.
  • Swiss National Bank sold 66,530 Puma Biotechnology shares in Q4 2021, an estimated $466K.
  • Swiss National Bank first reported a position in Puma Biotechnology in Q2 2014 and held it in 30 quarters.
  • Swiss National Bank's Puma Biotechnology position peaked at $7.18M in Q1 2015.
  • 102 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2021.

Based on Swiss National Bank's 13F filing for Q4 2021, filed 8 Feb 2022.